AUTHORS
John N Allan, M.D., Seok-Goo Cho, MD, PhD2, Monica Tani3, Geoff Chong, MD, PhD4, Tae Min Kim, MD, PhD5, Michal Taszner, MD6, Ana Jiménez Ubieto, MD, PhD7, Emmanuel Bachy I, MD, PhD8, Catherine Thieblemont, MD, PhD9, Francesca Gaia Rossi10, Jae-Cheol Cho11, Cecilia Carpio Segura, MD12, Sylvain Choquet, MD13, Stefano Luminari Sr, MD14, Tsai-Yun Chen, MD15, Deepa Jagadeesh, MD, MPH16, Rakhee Vaidya17, Thomas Weber, MD18, David Cunningham19, David Lewis, PhD, MBChB20, Jose C Villasboas, MD21, Yuan Cheng, PhD22, Amulya Uppala, PharmD23, Hesham Mohamed, MD24, Manjusha Namuduri, MD, MHA25, Pier Luigi Zinzani, MD, PhD26
AFFILIATIONS
1 Weill Cornell Medicine, New York, New York, United States
2 The Catholic University of Korea, Seoul St. Mary’s Hospital, Seoul, Korea, Rep. of South
3 Ospedale 'Santa Maria delle Croci' di Ravenna, Ravenna, Italy
4 Olivia Newton-John Cancer Wellness & Research Centre, Heidelberg, Victoria, Australia
5 Seoul National University Hospital, Seoul, Korea, Rep. of South
6 Medical University of Gdansk, University Clinical Center, Gdansk, Poland
7 Hospital Universitario 12 de Octubre, Madrid, Spain
8 Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France
9 Université Paris Cité, Assistance; Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France
10 Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
11 Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea, Rep. of South
12 University Hospital Vall d'Hebron, University Autònoma of Barcelona (UAB), Barcelona, Spain
13 Pitié-Salpêtrière University Hospital, Sorbonne University, AP-HP, Paris, France
14 Azienda Unità Sanitaria Locale – IRCCS of Reggio Emilia and University of Modena and Reggio Emilia, Reggio Emilia and Modena, Italy
15 National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
16 Cleveland Clinic, Cleveland, Ohio, United States
17 Atrium Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
18 University Hospital Halle, Halle (Saale), Germany
19 Royal Marsden Hospital, The Royal Marsden NHS Foundation Trust, London, United Kingdom
20 Derriford Hospital, University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom
21 Mayo Clinic, Rochester, Minnesota, United States
22 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
23 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
24 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
25 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
26 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Bologna, Italy
ABSTRACT
Introduction
Marginal zone lymphoma (MZL) is a heterogeneous, indolent B-cell non-Hodgkin lymphoma (B-NHL), comprising 3 subtypes: extranodal (EMZL), nodal (NMZL), and splenic (SMZL). Treatment options for relapsed/refractory (R/R) MZL remain limited. Approved small molecule therapies (e.g., Bruton tyrosine kinase inhibitors [BTKi]) typically show low complete response (CR) rates, and outcomes are poor for patients in high-risk subgroups (e.g., POD24), highlighting the need for new therapies. Odronextamab is a CD20×CD3 bispecific antibody that has demonstrated encouraging results in pts with R/R MZL (objective response rate [ORR] and CR both 77.1%; n=35; Kim TM et al. Blood 2024) from the ELM-2 study (NCT03888105). Here, we present an updated analysis of pts with R/R MZL in ELM-2 with the primary analysis results to follow.
Methods
Eligible patients were aged ≥18 yrs, with MZL (EMZL, NMZL, or SMZL) that was R/R after ≥2 prior lines of systemic therapy; prior BTKi treatment was allowed. Intravenous odronextamab monotherapy was administered in 21-day cycles, with optimized step-up dosing in Cycle (C) 1 to help mitigate the risk of cytokine release syndrome (CRS), followed by 80 mg weekly in C2–4, then maintenance 160 mg once every 2 weeks (Q2W) until disease progression/unacceptable toxicity. Pts with a CR for ≥9 months switched from 160 mg Q2W to Q4W. Primary endpoint was ORR per Lugano criteria by independent central review (ICR). Key secondary endpoints were CR rate, duration of response (DOR) and progression-free survival (PFS) by ICR, overall survival (OS), and safety.
Results
At the Oct 1, 2025 data cut-off, 78 patients (EMZL, n=34; NMZL, n=32; SMZL, n=11; unknown, n=1) were enrolled: median age 64.5 (range 33–85) yrs; male 48.7%; Ann Arbor III/IV 82.1%; median of 2 (range 1–8) prior lines of therapy. Of all patients, 28.2% were double-refractory to anti-CD20 and alkylator antibody, 39.7% had prior BTKi treatment, 37.2% had prior bendamustine treatment, and 42.3% had POD24. Overall, median odronextamab exposure was 34.5 weeks (range 2.0–205.4), and 48.7% of patients had ongoing treatment at data cut-off.
At median follow-up of 9.2 months (95% confidence interval [CI] 7.5–12.4), investigator-assessed ORR in efficacy-evaluable pts was 76.6% (59/77), and CR rate was 68.8%. ORR was 84.8%, 75.0%, and 63.6%, and CR rate was 81.8%, 59.4%, and 63.6%, for EMZL, NMZL, and SMZL, respectively. ORR was generally consistent across subgroups, including double refractory (72.7%), POD24 (69.7%), prior BTKi (76.7%), and age ≥75 yrs (81.3%). For the overall cohort, median DOR was not reached (NR; 95% CI not estimable [NE]–NE), with 12- and 24-mo DOR rates of 85.7% (95% CI 67.7–94.1) and 80.3% (59.2–91.2), respectively; median duration of CR, PFS, and OS were all NR (NE–NE).
All patients experienced treatment-emergent adverse events (TEAEs), with Grade (Gr) ≥3 TEAEs in 83.3% of pts. Overall, 15.4% of patients (EMZL 8.8%/ NMZL 15.6%/ SMZL 27.3%) discontinued treatment due to TEAEs. There were 3 deaths due to TEAEs (NMZL, n=1: Pneumocystis jirovecii pneumonia [PJP]; SMZL, n=2: acute respiratory failure [n=1], multiple organ dysfunction and hemodynamic instability [n=1]). The most common any Gr TEAEs were CRS (55.1%), pyrexia (33.3%), and anemia (32.1%); most common Gr ≥3 TEAEs were neutropenia (25.6%), increased aspartate aminotransferase, and decreased neutrophil count (15.4% each). The TEAE profile was similar across all subtypes. With the optimized step-up regimen (0.7/4/20 mg), CRS was reported in 57.6% (34/59) of patients (Gr 1, 33.9%; Gr 2, 22.0%; Gr 3, 0%; Gr 4, 1.7%, in 1 patient with high baseline white blood cell and absolute lymphocyte counts). One single event of ICANS was reported (Gr 1). Infections occurred in 71.8% of patients (Gr ≥3 29.5%); one patient died due to PJP.
Conclusions
Odronextamab is the only T-cell engaging therapy that demonstrated high rates of deep response with an overall CR rate of nearly 70% and median DOR NR. High responses were also observed across all R/R MZL subtypes (CR rate: EMZL, 81.8%; NMZL, 59.4%; SMZL, 63.6%). Importantly, high response rates were observed in patient subgroups with limited treatment options including those who are high-risk, heavily pretreated, or with POD24. The safety of odronextamab was manageable, with a similar profile to that observed in other B-NHL types. Primary analysis results, with ~18 months of follow-up, will be presented.
DISCLOSURES
John N Allan, M.D.: BeOne Medicines - Research Funding; BMS - Research Funding; Genentech - Research Funding; Adaptive Biotechnologies - Research Funding; Merck - Consultancy (Includes expert testimony); NeoGenomics - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Adaptive Biotechnologies - Consultancy (Includes expert testimony); Lilly - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); Pharmacyclics - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); BeOne Medicines - Consultancy (Includes expert testimony)